Figure 1From: Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma Selection diagram for studies comparing bevacizumab with interferon, sunitinib, and pazopanib to interferon alone or one another as first-line therapy for patients with clear cell renal cell carcinoma. Back to article page